NASDAQ · ICLR
Healthcare · Medical - Diagnostics & Research
$164.11
Down-$5.57 (-3.28%)
Updated Sep 20, 2026, 11:51 AM
SID Score
6.6/10
Composite research score
Smart Money
56/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
ICLR closed at $164.11 after 19 trading sessions, down 5.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $169.50 | $169.50 | $162.585 | $164.11 | 1.12M |
| Sep 17, 2026 | $175.01 | $177.50 | $169.44 | $169.68 | 1.17M |
| Sep 16, 2026 | $173.51 | $175.59 | $172.09 | $173.94 | 818.59K |
| Sep 15, 2026 | $168.02 | $172.94 | $167.715 | $172.45 | 862.42K |
| Sep 14, 2026 | $171.51 | $173.40 | $167.795 | $168.93 | 1.33M |
| Sep 11, 2026 | $165.68 | $175.63 | $165.68 | $169.31 | 1.71M |
| Sep 10, 2026 | $159.27 | $166.53 | $156.70 | $165.69 | 1.14M |
| Sep 9, 2026 | $158.71 | $161.76 | $157.255 | $159.51 | 801.14K |
| Sep 8, 2026 | $162.30 | $162.42 | $158.04 | $158.34 | 949.59K |
| Sep 4, 2026 | $159.94 | $165.915 | $159.50 | $164.85 | 796.4K |
| Sep 3, 2026 | $159.87 | $164.35 | $159.545 | $163.58 | 594.05K |
| Sep 2, 2026 | $161.88 | $164.235 | $158.66 | $159.84 | 893.17K |
| Sep 1, 2026 | $165.24 | $165.355 | $160.01 | $161.40 | 604.61K |
| Aug 31, 2026 | $169.91 | $170.41 | $163.565 | $164.99 | 707.46K |
| Aug 28, 2026 | $169.41 | $170.42 | $165.70 | $170.02 | 314.63K |
| Aug 27, 2026 | $168.84 | $174.115 | $168.27 | $169.72 | 376.59K |
| Aug 26, 2026 | $165.88 | $169.825 | $165.445 | $168.93 | 414.1K |
| Aug 25, 2026 | $172.69 | $173.00 | $168.01 | $168.91 | 444.91K |
| Aug 24, 2026 | $170.81 | $174.44 | $168.375 | $173.48 | 420.72K |
The latest Smart Investors Daily articles mentioning ICLR.
ICLR research
Company profile and research snapshot.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jun 30, 2026 | Truist Securities | Buy | — |
| Jun 26, 2026 | Mizuho | Outperform | — |
Generated Sep 20, 2026, 1:13 PM
ICLR shares declined 3.28% today amid mixed insider activity and a cautious analyst outlook. While several executives exercised stock options, a significant price target reduction from Citigroup is weighing on investor sentiment and overshadowing the insider buying signals.
Bottom line: ICLR's 3.28% decline appears primarily driven by Citigroup's price target reduction to $175, which outweighs neutral-to-positive signals from executive option exercises. Investors should watch for management commentary addressing analyst concerns and any updates on contract wins or growth drivers to determine if this pullback represents a buying opportunity or signals deeper challenges ahead.
Benzinga · Sep 18, 2026
Disclosed in a recent SEC filing on September 18, CLIMAX, Director at Icon (NASDAQ:ICLR), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on Friday
Benzinga · Sep 18, 2026
In a new SEC filing on September 18, it was revealed that McCague, Board Member at Icon (NASDAQ:ICLR), executed a significant exercise of company stock options. What Happened: A notable Form 4 filing on Friday with the
Benzinga · Sep 18, 2026
Martin Ronan Murphy, Board Member at Icon (NASDAQ:ICLR), reported a large exercise of company stock options on September 18, according to a new SEC filing. What Happened: Murphy, Board Member at Icon, exercised stock
Benzinga · Sep 18, 2026
Citigroup analyst Albert Hu maintains Icon (NASDAQ:ICLR) with a Neutral and lowers the price target from $180 to $175.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICLR.
